Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): a first-in-human, multicentre, phase 1–2 trialJohann S. de Bono, Ulrik Lassen, Jean-Pascal Machiels et al.|The Lancet Oncology|2019Cited by 228
A phase I/II first-in-human trial of oral SRA737 (a Chk1 inhibitor) given in combination with low-dose gemcitabine in subjects with advanced cancer.Udai Banerji, Robert H. Jones, Elizabeth Ruth Plummer et al.|Journal of Clinical Oncology|2019Cited by 20